March 2014

TBO-Filgrastim (Granix)

March 12, 2014

Formulary Drug Review

Tbo-filgrastim (Granix) is FDA approved to reduce the duration of severe neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy with significant evidence of febrile neutropenia.

Liposomal Bupivacaine as a Foundation for Multimodal Analgesia in the Postoperative Setting

March 12, 2014

Pharmacist Rounds

A 50-year-old male with a history of benign prostatic hyperplasia, chronic obstructive pulmonary disease, and type 2 diabetes mellitus is admitted for a laparoscopic colectomy. The patient's surgeon requests a pharmacy consultation to develop a multimodal, opioid-sparing pain control regimen.

Avoidable Readmissions

March 12, 2014

Viewpoints

In the past year, more than 2200 hospitals have been penalized $280 million for "excessive" readmission rates under the Centers for Medicare & Medicaid Services' Readmissions Reduction Program, and the penalties will become more severe as the maximum penalty rises to 3% by 2014.